Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) – Pipeline Review, H2 2017’, provides in depth analysis on Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Genetic Disorders and Musculoskeletal Disorders under development targeting Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

The report reviews Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics and enlists all their major and minor projects

The report assesses Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Bristol-Myers Squibb Company

Eisai Co Ltd

Eli Lilly and Company

Heptares Therapeutics Ltd

Johnson & Johnson

Merz Pharma GmbH & Co KgaA

Novartis AG

Richter Gedeon Nyrt

Sumitomo Dainippon Pharma Co Ltd

Toray Industries Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Overview 8

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 22

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Companies Involved in Therapeutics Development 23

Addex Therapeutics Ltd 23

Aevi Genomic Medicine Inc 23

Bristol-Myers Squibb Company 24

Eisai Co Ltd 24

Eli Lilly and Company 25

Heptares Therapeutics Ltd 25

Johnson & Johnson 26

Merz Pharma GmbH & Co KgaA 26

Novartis AG 27

Richter Gedeon Nyrt 27

Sumitomo Dainippon Pharma Co Ltd 28

Toray Industries Inc 28

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Drug Profiles 29

alloswitch-1 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BMS-952048 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

BMS-955829 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

dipraglurant ER - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

dipraglurant IR - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Drug to Antagonize mGluR5 for Fragile X Syndrome and 16p11.2 Microdeletion Syndrome - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

DSR-98776 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

fasoracetam - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

GET-73 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

HTL-14242 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

JNJ-46778212 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

LSN-2814617 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

mavoglurant - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

PAM-12 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Agonize Metabotropic Glutamate Receptor 5 for Cognitive Disorders - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecule to Antagonize mGlu5 for Persistent Pain - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Antagonize mGluR5 for CNS Disorders - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Agonize mGluR5 for Schizophrenia - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Antagonize mGluR5 for Anxiety - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecules to Antagonize MGLUR5 for Anxiety Disorders - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

VU-0092273 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

VU-0431316 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

VU-0463841 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

VU-0467558 - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Dormant Products 62

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Discontinued Products 65

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Product Development Milestones 67

Featured News & Press Releases 67

May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001 67

Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 67

Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD 69

Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001 69

Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome 70

Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents 70

Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder 71

Oct 17, 2016: Addex Therapeutics to Conduct Phase IIa Proof of Concept Study of Dipraglurant in Focal Cervical Dystonia 72

Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD 73

Jun 02, 2016: Addex Dipraglurant Positive Phase 2 Data in PD-LID Published in Leading Peer Reviewed Journal of the Movement Disorder Society 73

Apr 11, 2016: Addex Reports Positive Results of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 74

Mar 15, 2016: Addex Reports Successful Completion of an mGlu5 Receptor Occupancy Study with Dipraglurant in Healthy Volunteers 76

Jan 11, 2016: Addex Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis of Data from the PD-LID Phase II Proof of Concept 77

Jan 04, 2016: Addex’ Dipraglurant Receives Orphan Drug Designation from the FDA for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease 77

Dec 17, 2015: Addex Reports Statistically Significant Positive Interim Data for Dipraglurant in Healthy Volunteer mGlu5 Receptor Occupancy Trial 78

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Number of Products under Investigation by Universities/Institutes, H2 2017 17

Products under Investigation by Universities/Institutes, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by Addex Therapeutics Ltd, H2 2017 23

Pipeline by Aevi Genomic Medicine Inc, H2 2017 23

Pipeline by Bristol-Myers Squibb Company, H2 2017 24

Pipeline by Eisai Co Ltd, H2 2017 24

Pipeline by Eli Lilly and Company, H2 2017 25

Pipeline by Heptares Therapeutics Ltd, H2 2017 25

Pipeline by Johnson & Johnson, H2 2017 26

Pipeline by Merz Pharma GmbH & Co KgaA, H2 2017 26

Pipeline by Novartis AG, H2 2017 27

Pipeline by Richter Gedeon Nyrt, H2 2017 27

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 28

Pipeline by Toray Industries Inc, H2 2017 28

Dormant Products, H2 2017 62

Dormant Products, H2 2017 (Contd..1), H2 2017 63

Dormant Products, H2 2017 (Contd..2), H2 2017 64

Discontinued Products, H2 2017 65

Discontinued Products, H2 2017 (Contd..1), H2 2017 66

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 19

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administrations, H2 2017 21

Number of Products by Stage and Molecule Types, H2 2017 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports